Do you want to read an article? Please log in or register.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Multiple Myeloma (MM)
Related content
Multiple Myeloma (MM)
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
Lancet Oncol
Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, Bone Working Group of the International Myeloma Working Group.
doi: 10.1016/S1470-2045(20)30559-3
COMMENTED
Multiple Myeloma (MM)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1016/S2352-3026(20)30070-3.
Multiple Myeloma (MM)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Lancet Oncol.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P
doi: 10.1016/
Multiple Myeloma (MM)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study
Lancet Haematol.
Richardson PG, Bringhen S, Voorhees P, Plesner T, Mellqvist UH, Reeves B, Paba-Prada C, Zubair H, Byrne C, Chauhan D, Anderson K, Nordström E, Harmenberg J, Palumbo A, Sonneveld P
doi: 10.1016/S2352-3026(20)30044-2.
Multiple Myeloma (MM)
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe
Expert Rev Hematol.
Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, de Wit E
doi: 10.1080/
Multiple Myeloma (MM)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Lancet Oncol.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, San Miguel J, Avet-Loiseau H
doi: 10.1016/
COMMENTED
Multiple Myeloma (MM)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
Lancet.
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ
doi: 10.1016/S0140-6736(20)30734-0.
Multiple Myeloma (MM)
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
Blood Cancer J
Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B
doi: 10.1038/s41408-021-00408-4
Multiple Myeloma (MM)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S, KEYNOTE-183 Investigators.
doi: 10.1016/